ACHIEVE LIFE SCIENCES, INC.

Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline. Its efforts center on addressing nicotine dependence by targeting adult combustible cigarette smoking and e-cigarette usage. Cytisinicline constitutes the organization's sole product candidate, developed to aid individuals seeking treatment for tobacco and nicotine addiction across the broader smoking cessation landscape.

The company operates across North America and Europe, maintaining facilities and operations in the United States, Canada, and the United Kingdom. Its principal executive offices are located in Bothell, Washington, alongside an executive office facility in Vancouver, British Columbia. Achieve relies on international plant sources grown outside the United States to secure necessary quantities of cytisinicline for its development activities.

Summary of the business section of Achieve Life Sciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had a total of 28 employees, of whom 11 were engaged in research and development functions, including clinical development, regulatory affairs and manufacturing, and 17 were engaged in general and administrative functions, including accounting and finance, administration, and commercial.”